Table 1.
Medication class | CKD stages 3 and 4 and predialysis stage 5 |
---|---|
Insulin | |
Glargine | No advised dose adjustment* |
Detemir | No advised dose adjustment* |
NPH | No advised dose adjustment* |
Regular | No advised dose adjustment* |
Aspart | No advised dose adjustment* |
Lispro | No advised dose adjustment* |
Glulisine | No advised dose adjustment* |
First-generation sulfonylureas | |
Acetohexamide** | Avoid use |
Chlorpropamide | eGFR 50–80: reduce dose by 50 % |
eGFR <50: avoid use | |
Tolazamide | Avoid use |
Tolbutamide | Avoid use |
Second-generation sulfonylureas | |
Glipizide | eGFR <30: use with caution |
Glimepiride | eGFR <60: use with caution |
eGFR <30: avoid use | |
Glyburide | Avoid use |
Gliclazide** | No dose adjustment |
Glinides | |
Repaglinide | No dose adjustment but may wish to use caution with eGFR <30 |
Nateglinide | eGFR <60: avoid use (but may consider use if patient is on hemodialysis) |
Biguanides | |
Metformin*** | Per FDA, do not use if serum Cr ≥ 1.5 mg/dL in men ≥ 1.4 mg/dL in women. |
Consider | |
eGFR ≥45-59: use caution with dose and follow renal function closely (every 3–6 months) | |
eGFR ≥30-44: max dose 1000 mg/day or use 50 % dose reduction. Follow renal function every 3 months. Do not start as new therapy. | |
eGFR <30: avoid use | |
Thiazolidinediones | |
Pioglitazone | No dose adjustment |
Rosiglitazone | No dose adjustment |
Alpha-glucosidase inhibitors | |
Acarbose | serum Cr >2 mg/dl: avoid use |
Miglitol | eGFR <25 or serum Cr >2 mg/dl: avoid use |
DPP-4 inhibitor | |
Sitagliptin | eGFR ≥50: 100 mg daily |
eGFR 30–49: 50 mg daily | |
eGFR < 30: 25 mg daily | |
Saxagliptin | eGFR > 50: 2.5 or 5 mg daily |
GFR ≤ 50: 2.5 mg daily | |
Linagliptin | No dose adjustment |
Alogliptin | eGFR >60: 25 mg daily |
eGFR 30–59: 12.5 mg daily | |
eGFR <30: 6.25 mg daily | |
SGLT2 inhibitors | |
Canagliflozin | eGFR 45 to < 60: max dose 100 mg once daily |
eGFR <45, avoid use | |
Dapagliflozin | eGFR < 60, avoid use |
Empagliflozin | eGFR < 45, avoid use |
Dopamine receptor agonist | |
bromocriptine mesylate | No dose adjustment known but not studied: use with caution |
Bile acid sequestrant | |
Colesevelam | No dose adjustment known but limited data |
GLP-1 Agonists | |
Exenatide | eGFR 30–50: use caution |
eGFR <30: avoid use | |
Liraglutide | No dose adjustment but use caution when starting or titrating the dose |
Albiglutide | No dose adjustment needed |
Dulaglutide | No dose adjustment needed |
Amylin analog | |
Pramlintide | No dose adjustment known but not studied in ESRD |
*Adjust dose based on patient response
**Not available in the U.S.
***Recommendations are controversial